BioSpace News Archive

Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda ® in Patients with Advanced Refractory Melanoma at Duke Cancer Institute.

Trueline Therapeutics Inc. today announced the successful completion of IND-enabling studies with MCL1 inhibitor TTX-810, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer.

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Israel-based Ornat Biochemicals and Laboratory Equipment to extend Parse’s reach in the Middle East.

Enzolytics, Inc. announced that the Company’s wholly owned subsidiary, Virogentics (VIRO), has received the analysis report from the Bulgarian Academy of Sciences determining the protein concentration, native enzyme concentration and peptide analysis, and amino acid sequence for Module 3 for the permitting by the European Medicine agency (“EMA ").

Cerevance today announced plans to present an oral presentation at the upcoming American Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 – June 2, 2023.

Wave Life Sciences Ltd. today announced it will highlight its leading RNA editing capability and its multimodal discovery and development platform at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 16-20, 2023, in Los Angeles, California.

X4 Pharmaceuticals, Inc. today announced that it has agreed to sell an aggregate of 42,784,203 shares of common stock (or pre-funded warrants in lieu thereof) to certain institutional accredited investors in a private investment in public equity (PIPE) financing.

SAB Biotherapeutics yesterday reported financial results for the first quarter ended March 31, 2023, and provided a company update.

NurExone Biologic Inc. (the “Company” or “NurExone”) (TSXV: NRX) (FSE: J90) (NRX.V) announces that the Company has received an issue notification from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent NO. 11,648,260, granted for the period of 20 years from filing date until March 27, 2039.